AVTX

Over the past six months (March 2026 - September 2026), Avalo Therapeutics experienced several stock-impacting events. In March 2026, the company reported 2025 financial results, business updates, and anticipated topline data from its Phase 2 LOTUS trial for abdakibart (AVTX-009) in Q2 2026, with cash expected to fund operations into 2028. Ron Philip was appointed to the board of directors in June 2026. In the second quarter of 2026, positive topline Phase 2 LOTUS data for abdakibart (AVTX-009) in moderate to severe hidradenitis suppurativa was reported, meeting its primary endpoint with strong HiSCR75 response rates. August 2026 saw the company detail its Q2 2026 loss, report an extended cash runway into 2029, and announce plans to initiate a registrational Phase 3 program for abdakibart in HS and submit an IND for AVTX-010 in the first half of 2027; Avalo was also added to the Russell 2000 and 3000 Indexes. In the month leading up to September 2026, the stock price decreased by 20.14%, though it had increased by 40.07% over the past 12 months.